The origins of oncomice: A history of the first transgenic mice genetically engineered to develop cancer

Genes and Development

Volumn 21, Issue 18, 2007, Pages 2258-2270

  Hanahan, Douglas ^a   Wagner, Erwin F ^b   Palmiter, Richard D ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Mouse models of human cancer; Oncogenes; Oncomouse patents; Transgenic mice; Tumors

Indexed keywords

CANCER GENETICS; CANCER MODEL; CANCER RESEARCH; CARCINOGENESIS; CLINICAL STUDY; GENE EXPRESSION; GENETIC ENGINEERING; HISTORY OF MEDICINE; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE; ONCOMOUSE; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LYMPHOMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; ONCOGENES; PANCREATIC NEOPLASMS; SKIN NEOPLASMS;

MUS MUSCULUS;

EID: 34548860125     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1583307     Document Type: Review

References (82)

1. Adams, J.M., Harris, A.W., Pinkert, C.A., Corcoran, L.M., Alexander, W.S., Cory, S., Palmiter, R.D., and Brinster, R.L. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538.
2. Adams, T., Alpert, S., and Hanahan, D. 1987. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic -cells. Nature 325: 223-228.
3. Bautch, V.L., Toda, S., Hassell, J.A., and Hanahan, D. 1987. Endothelial cell tumors develop in transgenic mice carrying polyoma virus middle T oncogene. Cell 20: 529-537.
4. Bearss, D.J., Subler, M.A., Hundley, J.E., Troyer, D.A., Salinas, R.A., and Windle, J.J. 2000. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene 19: 1114-1122.
5. Bearss, D.J., Lee, R.J., Troyer, D.A., Pestel, L.R.G., and Windle, J.J. 2002. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res. 62: 2077-2084.
6. Bergers, G., Brekken, R., McMahon, J., Vu, T., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2: 737-744.
7. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. 2003. Benefits of targeting both pericytes and endothelial cells in tumor vasculature with kinase inhibitors. J. Clin. Invest. 111: 1287-1295.
8. Blaug, S., Chien, C., and Shuster, M.J. 2004. Managing innovation: University-industry partnerships and the licensing of the Harvard oncomouse. Nat. Biotechnol. 22: 761-763.
9. Bossy-Wetzel, E., Bravo, R., and Hanahan, D. 1992. Transcription factors JunB and c-Jun are selectively up-regulated and functionally implicated in fibrosarcoma development. Genes & Dev. 6: 2340-2351.
10. Brinster, R.L., Chen, H.Y., Trumbauer, M., Senear, A.W., Warren, R., and Palmiter, R.D. 1981. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell 27: 223-231.
11. Brinster, R.L., Chen, H.Y., Messing, A., van Dyke, T., Levine, A.J., and Palmiter, R.D. 1984. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 37: 367-379.
12. Casanovas, O., Hicklin, D.J., Bergers, G., and Hanahan, D. 2005. Drug resistance by evasion of of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309.
13. Chen, J., Tobin, G.J., Pipas, J.M., and Van Dyke, T. 1992. Tantigen mutant activities in vivo: Roles of p53 and pRB binding in tumorigenesis of the choroid plexus. Oncogene 7: 1167-1175.
14. Christofori, G., Naik, P., and Hanahan, D. 1994. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369: 414-418.
15. Costantini, F. and Lacy, E. 1981. Introduction of a rabbit β-globin gene into the mouse germ line. Nature 294: 92-94.
16. Coussens, L.M., Tinkle, C.L., Hanahan, D., and Werb, Z. 2000. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
17. David, J.P., Mehic, D., Bakiri, L., Schilling, A.F., Mandic, V., Priemel, M., Idarraga, M.H., Reschke, M.O., Hoffmann, O., Amling, M., et al. 2005. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J. Clin. Invest. 115: 664-672.
18. de Visser, K.E., Korets, L.V., and Coussens, L.M. 2005. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423.
19. Egle, A., Harris, A.W., Bouillet, P., and Cory, S. 2004. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl. Acad. Sci. 101: 6164-6169.
20. Eischen, C.M., Weber, J.D., Roussel, M.F., Sherr, C.J., and Cleveland, J.L. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes & Dev. 13: 2658-2669.
21. Evers, B. and Jonkers, J. 2006. Mouse models of BRCA1 and BRCA2 deficiency: Past lessons, current understanding and future prospects. Oncogene 25: 5885-5897.
22. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
23. Giraudo, E., Inoue, M., and Hanahan, D. 2004. An aminobisphosphonate targets MMP9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114: 623-633.
24. Gordon, J.W., Scangos, G.A., Plotkin, D.J., Barbosa, J.A., and Ruddle, F.H. 1980. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc. Natl. Acad. Sci. 77: 7380-7384.
25. Guy, C.T., Cardiff, R.D., and Muller, W.J. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12: 954-961.
26. Hanahan, D. 1985. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115-122.
27. Hanahan, D. and Folkman, J. 1996. Parameters and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-354.
28. Haupt, Y., Alexander, W.S., Barri, G., Klinken, S.P., and Adams, J.M. 1991. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eu-myc transgenic mice. Cell 65: 753-763.
29. Heller, M.A. and Eisenberg, R.S. 1998. Can patents deter innovation? The anticommons in biomedical research. Science 280: 698-701.
30. Hemann, M.T., Fridman, J.S., Zilfou, J.T., Hernando, E., Paddison, P.J., Cordon-Cardo, C., Hannon, G.J., and Lowe, S.W. 2003. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 33: 396-400.
31. Holman, C. 2006. Clearing a path through the patent thicket. Cell 125: 629-633.
32. Huang, A.L., Ostrowski, M.C., Berard, D., and Hager, G.L. 1981. Glucocorticoid regulation of the Ha-MuSV p21 gene conferred by sequences from mouse mammary tumor virus. Cell 27: 245-255.
33. Jacks, T. 1996. Tumor suppressor gene mutations in mice. Annu. Rev. Genet. 30: 603-636.
34. Jacobs, J.J., Scheijen, B., Voncken, J.W., Kieboom, K., Berns, A., and van Lohuizen, M. 1999. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes & Dev. 13: 2678-2690.
35. Jaenisch, R. and Mintz, B. 1974. Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. Proc. Natl. Acad. Sci. 71: 1250-1254.
36. Jochum, W., Passegue, E., and Wagner, E.F. 2001. AP-1 in mouse development and tumorigenesis. Oncogene 20: 2401-2412.
37. Jolicoeur, C., Hanahan, D., and Smith, K. 1994. T cell tolerance towards a transgenic β cell antigen and transcription of endogenous pancreatic genes in the thymus. Proc. Natl. Acad. Sci. 91: 6707-6711.
38. Joyce, J.A., Baruch, A., Kareem Chehade, K., Nicole Meyer-Morse, N., Fong-Ying Tsai, F.Y., Hager, J., Bogyo, M., and Hanahan, D. 2004. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5: 443-453.
39. Joyce, J.A., Freeman, C., Meyer-Morse, N., Parish, C.R., and Hanahan, D. 2005. A functional mimetic implicates heparanase and its target heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24: 4037-4051.
40. Kelly, P.N., Puthalakath, H., Adams, J.M., and Strasser, A. 2007. Endogenous bcl-2 is not required for the development of Eu-myc-induced B cell lymphoma. Blood 109: 4907-4913.
41. Kerbel, R.S. 2003. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: Better than commonly perceived-but they can be improved. Cancer Biol. Ther. 24: 134-139.
42. Lacey, M., Alpert, S., and Hanahan, D. 1986. Bovine papillomavirus genome elicits skin tumours in transgenic mice. Nature 322: 609-612.
43. Land, H., Parada, L.F., and Weinberg, R.A. 1983. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304: 596-602.
44. Langdon, W.Y., Harris, A.W., Cory, S., and Adams, J.M. 1986. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 47: 11-18.
45. Leder, P. and Stewart, T. 1988. Transgenic non-human mammals. US Patent 4736866.
46. Leder, P. and Stewart, T. 1992. Method for providing a cell culture from a transgenic non-human mammals. US Patent 5087571.
47. Leder, P. and Stewart, T. 1999. Testing method using transgenic mice expressing an oncogene. U.S. Patent 5925803.
48. Leder, A., Pattengale, P.K., Kuo, A., Stewart, T.A., and Leder, P. 1986. Consequences of widespread deregulation of the c-myc gene in transgenic mice: Multiple neoplasms and normal development. Cell 45: 485-495.
49. Marshall, E. 2002. Dupont ups the ante on use of Harvard's oncomouse. Science 296: 1212-1213.
50. McCarthy, S.A., Symonds, H.S., and Van Dyke, T. 1994. Regulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53. Proc. Natl. Acad. Sci. 91: 3979-3983.
51. Nozawa, H., Chiu, C., and Hanahan, D. 2006. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. 103: 12493-12498.
52. Ornitz, D.M., Palmiter, R.D., Messing, A., Hammer, R.E., Pinkert, C.A., and Brinster, R.L. 1985. Elastase I promoter directs expression of human growth hormone and SV40 T-antigen genes to pancreatic acinar cells in transgenic mice. Cold Spring Harb. Symp. Quant. Biol. 50: 399-409.
53. Ornitz, D.M., Hammer, R.E., Messing, A., Palmiter, R.D., and Brinster, R.L. 1987. Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science 238: 188-193.
54. Palmiter, R.D. and Brinster, R.L. 1986. Germ-line transformation of mice. Annu. Rev. Genet. 20: 465-499.
55. Palmiter, R.D., Brinster, R.L., Hammer, R.E., Trumbauer, M.E., Rosenfeld, M.G., Birnbberg, N.C., and Evans, R.M. 1982a. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 300: 611-615.
56. Palmiter, R.D., Chen, H.Y., and Brinster, R.L. 1982b. Differential regulation of metallothionein-thymidine kinase fusion genes in transgenic mice and their offspring. Cell 29: 701-710.
57. Palmiter, R.D., Norstedt, G., Gelinas, R.E., Hammer, R.E., and Brinster, R.L. 1983. Metallothionein-human growth hormone genes stimulate growth of mice. Science 222: 809-814.
58. Palmiter, R.D., Chen, H.Y., Messing, A., and Brinster, R.L. 1985. SV40 enhancer and large-T antigen are instrumental in development of choroids plexus tumors in transgenic mice. Nature 316: 457-460.
59. Perl, A.K., Wilgenbus, P., Dahl, U., Semb, H., and Christofori, G. 1998. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392: 190-193.
60. Quaife, C.J., Pinkert, C.A., Ornitz, D.M., Palmiter, R.D., and Brinster, R.L. 1987. Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell 48: 1023-1034.
61. Ray, D., Terao, Y., Fuhrken, P.G., Ma, Z.Q., DeMayo, F.J., Christov, K., Heerema, N.A., Franks, R., Tsai, S.Y., Papoutsakis, E.T., et al. 2007. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res. 67: 984-991.
62. Rüther, U., Garber, C., Komitowski, D., Muller, R., and Wagner, E.F. 1987. Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 325: 412-416.
63. Rüther, U., Komitowski, D., Schubert, F.R., and Wagner, E.F. 1989. c-fos expression induces bone tumors in transgenic mice. Oncogene 4: 861-865.
64. Schmitt, C.A., McCurrach, M.E., de Stanchina, E., Wallace-Brodeur, R.R., and Lowe, S.W. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes & Dev. 13: 2670-2677.
65. Schmitt, C.A., Rosenthal, C.T., and Lowe, S.W. 2000. Genetic analysis of chemoresistance in primary murine lymphomas. Nat. Med. 6: 1029-1035.
66. Schmitt, C.A., Fridman, J.S., Yang, M., Lee, S., Baranov, E., Hoffman, R.M., and Lowe, S.W. 2002. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335-346.
67. Sharpless, N.E. and DePinho, R.A. 2006. The mighty mouse: The role of mouse models in cancer drug development. Nat. Rev. Drug Disc. 5: 741-754.
68. Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., and Leder, P. 1987. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49: 465-475.
69. Smith, K.M., Olson, D., Hirose, R., and Hanahan, D. 1997. Pancreatic gene expression in rare cells of thymic medulla: Evidence for functional contribution to T cell tolerance. Int. Immunol. 9: 1355-1365.
70. Stewart, T.A., Wagner, E.F., and Mintz, B. 1982. Human β-globin gene sequences injected into mouse eggs, retained in adults, and transmitted to progeny. Science 217: 1046-1048.
71. Stewart, T.A., Pattengale, P.K., and Leder, P. 1984. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38: 627-637.
72. Strasser, A., Harris, A.W., Bath, M.L., and Cory, S. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348: 331-333.
73. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711.
74. Ursini-Siegel, J., Schade, B., Cardiff, R.D., and Muller, W.J. 2007. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat. Rev. Cancer 7: 389-397.
75. van Lohuizen, M., Verbeek, S., Scheijen, B., Wientjens, E., van der Gulden, H., and Berns, A. 1991. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65: 737-752.
76. Vaux, D.L., Cory, S., and Adams, J.M. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442.
77. Wagner, E.F. 1990. On transferring genes into stem cells and mice. EMBO J. 9: 3024-3032.
78. Wagner, E.F., Stewart, T.A., and Mintz, B. 1981. The human -globin gene and a functional viral thymidine kinase gene in developing mice. Proc. Natl. Acad. Sci. 78: 5016-5020.
79. Wang, Z.Q., Liang, J., Schellander, K., Wagner, E.F., and Grigoriadis, A.E. 1995. c-fos-induced osteosarcoma formation in transgenic mice: Cooperativity with c-jun and the role of endogenous c-fos. Cancer Res. 55: 6244-6251.
80. Wendel, H.G., de Stanchina, E., Fridman, J.S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., and Lowe, S.W. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.
81. Williams, R.L., Courtneidge, S.A., and Wagner, E.F. 1988. Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene. Cell 52: 121-131.
82. Xian, X., Hakansson, J., Stahlberg, A., Lindblom, P., Betsholtz, C., Gerhardt, H., and Semb, H. 2006. Pericytes limit tumor cell metastasis. J. Clin. Invest. 116: 642-651.